Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.71 |
| ▸ | PPARA | Q07869 | 15/20 | 0.71 |
| ▸ | PPARD | Q03181 | 8/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5915216 | 0.93 | PPARG (0.68) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL3279259 | 0.91 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL4746637 | 0.90 | FFAR1 (0.77) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL14382549 | 0.90 | PPARG (0.71) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL4389208 | 0.88 | PPARG (0.79) | PPARGPPARAPPARD | |
| SCHEMBL9537307 | 0.88 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL4029375 | 0.88 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL3279660 | 0.88 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL3283978 | 0.87 | PPARG (0.77) | PPARGPPARAPPARD | |
| SCHEMBL6969645 | 0.87 | PPARG (0.67) | PPARGPPARAPPARDFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132145-B2 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus | NEW YORK UNIVERSITY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140296141-A1 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296141-A1 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus | LPL, ADIPOR2, EBP | PPARG 42/4885PPARA 24/4885PPARD 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.